跳至主要内容
临床试验/JPRN-UMIN000048096
JPRN-UMIN000048096已完成未知

A multicenter retrospective observational study evaluating the safety and efficacy of immune checkpoint inhibitors in patients with advanced or recurrent lung cancer after COVID-19 vaccination (NEJ061) - NEJ061 study

Specified Nonprofit Corporation North East Japan Study Group0 个研究点目标入组 850 人开始时间: 2022年6月18日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
850

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. active concomitant malignancy 2. interstitial pneumonia or pulmonary fibrosis detectable on CT scan 3. re-administration of immune checkpoint inhibitors (previously PD or toxic discontinuation) 4. with active hepatitis B or hepatitis C 5. with autoimmune disease or a history of autoimmune disease requiring steroid therapy 6. other than autoimmune diseases, continuous systemic or intravenous administration of steroids at doses higher than 10 mg / day in terms of prednisolone is required, and immunosuppressants are used 7. with a history of human immunodeficiency virus

研究者

发起方
Specified Nonprofit Corporation North East Japan Study Group

相似试验